


Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) ~~Crystalline~~ A crystalline form of Compound I, which compound has the formula



,wherein the crystalline form of Compound I exhibits one or more of: (i) the X-Ray powder diffractogram shown in Figure 1 as measured using CuK α radiation; (ii) reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1; (iii) the solid state Carbon-13 NMR spectrum shown in Figure 7; or (iv) the NIR reflectance spectrum shown in Figure 10.

2. (Canceled)

3. (Canceled)

4. (Previously Presented) The crystalline form of claim 1, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1.

5. (Previously Presented) The crystalline form of claim 1, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 5.2, 7.3, 8.1, 10.1, 10.4, 11.2, 13.2, 15.1, 15.5, 17.3, 21.7, 23.8, and 25.1.


6. (Currently amended) The crystalline form of claim 1, wherein the crystalline form of Compound I has a crystal structure with the following characteristics at 122 K: Space group: ~~P2₁2₁2₁~~ P2₁2₁2₁, Unit cell dimensions: a = 10.227(2) Å, b = 23.942(2) Å and c = 24.240(2) Å, α = 90°, β = 90°, γ = 90°, 2 molecules in the asymmetric unit.

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Currently amended) A crystalline form of Compound I, which compound has the formula



~~The crystalline form of claim 1,~~


wherein the crystalline form of Compound I exhibits one or more of: (i) the X-Ray powder diffractogram shown in Figure 3 as measured using CuK α radiation; (ii) reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.6, 11.5, 12.5, 16.7, 19.3, and 28.1; (iii) the solid state Carbon-13 NMR spectrum shown in Figure 9; or (iv) the NIR reflectance spectrum shown in Figure 12.

11. (Currently amended) The crystalline form of claim ~~[[1]]~~ 10, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.6, 11.5, 12.5, 16.7, 19.3, and 28.1.

12. (Currently amended) The crystalline form of claim [[1]] 10, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 7.5, 8.3, 9.6, 11.5, 11.8, 12.5, 15.9, 16.3, 16.7, 17.2, 18.0, 19.3, 21.0, and 28.1.

13. (Cancelled)

14. (Currently amended) A crystalline form of Compound I, which compound has the
formula



~~The crystalline form of claim 1,~~
wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.7, 12.1, 16.1, 18.3, 22.1, 22.2, 25.7, and 25.8.

15. (Currently amended) The crystalline form of claim [[1]] 14, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 7.3, 8.3, 9.7, 11.1, 11.7, 12.1, 15.6, 16.1, 17.3, 18.3, 20.9, 22.1, 22.2, 25.7, and 25.8.

16. (Cancelled)


17. (Cancelled)

18. (Cancelled)

19. (Previously presented) The crystalline form of claim 1, which is substantially pure.

Claims 20 through 34 are cancelled.

35. (Previously presented) A method for preparing crystalline Compound I, comprising forming crystalline Compound I in a solvent of methanol with 0% to about 8% water, wherein Compound I has the formula



36. (Original) The method of claim 35, comprising crystallizing by precipitation Compound I from the solvent and separating the solvent from the obtained crystalline Compound I.

37. (Previously presented) The method of claim 35, wherein said crystalline Compound I exhibits one or more of the following: (i) the X-Ray powder diffractogram shown in Figure 1 as measured using CuK α radiation; (ii) reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2- theta angles: 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1; (iii) the solid state Carbon-13 NMR spectrum shown in Figure 7; or (iv) the NIR reflectance spectrum shown in Figure 10.

Claims 38 through 46 are cancelled.

47. (Currently amended) A solid pharmaceutical composition comprising ~~an effective amount of~~
the crystalline form of Compound I of claim 1 and a pharmaceutically acceptable excipient.

Claims 48-54 and claims 55-59 are cancelled.